A warning letter is a serious communication from the USFDA that signifies a potential risk to public health or safety due to ...

Chairman and Managing Director Glenn Saldanha said on Monday that the company has several assets under development, including ...

With the stock currently trading at Rs 2,225.80, Glenmark Pharma has shown a positive movement of 2.05% in today's session.

Glenmark’s outlicensing deal with AbbVie for a novel drug for blood cancer under development sets a new course for the ...

Glenmark Pharmaceuticals receives FDA warning letter for Indore facility, commits to resolving compliance issues promptly.

By Kashish Tandon (Reuters) -Shares of India's Glenmark Pharmaceuticals jumped 10% to a record high on Friday, a day after ...

In an official filing, the company stated that it does not anticipate the warning letter will disrupt supply chains or affect ...

Glenmark Pharmaceuticals Ltd is quoting at Rs 2214.7, up 1.54% on the day as on 12:49 IST on the NSE. The stock is up 57.28% in last one year as compared to a 1.88% jump in NIFTY and a 7.85% jump in ...

Glenmark Pharmaceuticals Ltd.’s licensing pact with AbbVie Inc. for its blood cancer drug is boosting optimism over Indian ...

Glenmark Pharma share price today: Shares of Glenmark Pharma surged 10 per cent, recording a 52-week high of ₹2,094.40 on ...

With a $2-billion cancer drug deal in its pocket, Glenmark’s licensing agreement with AbbVie not only unlocks a potential ...

HSBC and Axis Capital are more bullish on its transformative impact and future growth prospects for Glenmark, while Nuvama ...